Treatment

T O A Oy prognosis malignant mesothelioma remains disappointing, although there modest improvements prognosis newer chemotherapies multimodality treatments. Treatment malignant mesothelioma earlier stages better prognosis, cures exceedingly . Clinical behavior malignancy affected y several factors including continuous mesothelial surface pleural cavity which favors local metastasis exfoliated cells, invasion underlying tissue other organs within pleural cavity, extremely g latency period between asbestos exposure development disease. T O A Oy histological subtype patient's g health status p predict prognosis.

Surgery

Surgery, y itself, proved disappointing. I large series, median survival surgery (including extrapleural pneumonectomy) y 11.7 months. However, research indicates varied success combination radiation chemotherapy (Duke, 2008). (F information multimodality therapy surgery, below). A pleurectomy/decortication common surgery, which lining chest rerelocated. L common extrapleural pneumonectomy (EPP), which lung, lining inside chest, -diaphragm pericardium rerelocated.

Radiation

F patients localized disease, tolerate radical surgery, radiation often given p-operatively consolidative treatment. T O A Oy entire -thorax treated radiation therapy, often given simultaneously chemotherapy. T approach using surgery followed y radiation chemotherapy pioneered y thoracic oncology Brigham & Women's Hospital Boston. Delivering radiation chemotherapy after radical surgery extended expectancy selected patient populations patients surviving 5 years. A p curative approach mesothelioma, radiotherapy commonly applied sites chest drain insertion, order prevent growth tumor along track chest .

Although mesothelioma generally resistant curative treatment radiotherapy alone, palliative treatment regimens sometimes relieve symptoms arising tumor growth, obstruction major blood vessel. Radiation therapy given alone curative intent never shown improve survival mesothelioma. T O A Oy necessary radiation treat mesothelioma surgically rerelocated would y toxic.

Chemotherapy

Chemotherapy y treatment mesothelioma proven improve survival randomised controlled trials. T O A Oy landmark study published 2003 y Vogelzang colleagues compared cisplatin chemotherapy alone combination cisplatin pemetrexed (brand Alimta) chemotherapy) patients received chemotherapy malignant pleural mesothelioma previously candidates aggressive "curative" surgery. T trial first report survival advantage chemotherapy malignant pleural mesothelioma, showing statistically significant improvement median survival 10 months patients treated cisplatin alone 13.3 months combination pemetrexed group patients received supplementation folate vitamin B12. Vitamin supplementation given patients trial pemetrexed related effects significantly patients receiving pemetrexed y received daily folate 500mcg intramuscular vitamin B12 1000mcg 9 weeks compared patients receiving pemetrexed without vitamin supplementation. T O A Oy objective response increased 20% cisplatin group 46% combination pemetrexed group. S effects nausea vomiting, stomatitis, diarrhoea common combination pemetrexed group y affected minority patients overall combination pemetrexed cisplatin tolerated patients received vitamin supplementation; quality g function tests improved combination pemetrexed group. I February 2004, United States F Dg Administration approved pemetrexed treatment malignant pleural mesothelioma. However, there still unanswered questions about optimal chemotherapy, including start treatment, optimal number cycles g.

Cisplatin combination raltitrexed shown improvement survival similar reported pemetrexed combination cisplatin, raltitrexed longer commercially available indication. F patients unable tolerate pemetrexed, cisplatin combination gemcitabine vinorelbine alternative, vinorelbine , although survival benefit shown these drugs. F patients cisplatin cannot used, carboplatin substituted -randomised shown lower response rates g rates haematological toxicity carboplatin-based combinations, albeit similar survival figures patients receiving cisplatin.

I January 2009, United States FDA approved using conventional therapies surgery combination radiation chemotherapy stage I II Mesothelioma after research conducted y nationwide study y D University concluded almost 50 point increase remission rates.

Immunotherapy

Treatment regimens involving immunotherapy yielded variable results. F example, intrapleural inoculation Bacillus Calmette-Guérin (BCG) attempt boost immune response, found benefit patient (while y benefit patients bladder cancer). Mesothelioma cells proved susceptible vitro lysis y LAK cells following activation y interleukin-2 (IL-2), patients undergoing particular therapy experienced major effects. Indeed, trial suspended unacceptably g levels IL-2 toxicity severity effects fever cachexia. Nonetheless, other trials involving interferon alpha proved encouraging 20% patients experiencing greater 50% reduction tumor combined minimal effects.

Heated Intraoperative Intraperitoneal Chemotherapy

A procedure known heated intraoperative intraperitoneal chemotherapy developed y P Sugarbaker Washington Cancer Institute. T O A Oy surgeon removes tumor possible followed y direct administration chemotherapy agent, heated between 40 48°C, abdomen. T O A Oy fluid perfused 60 120 minutes drained.

T technique permits administration g concentrations selected drugs abdominal pelvic surfaces. Heating chemotherapy treatment increases penetration drugs tissues. Also, heating itself damages malignant cells normal cells.

T technique patients malignant pleural mesothelioma.

Multimodality Therapy

A standard approaches treating solid tumors—radiation, chemotherapy, surgery—have investigated patients malignant pleural mesothelioma. Although surgery, y itself, y effective, surgery combined adjuvant chemotherapy radiation (trimodality therapy) produced significant survival extension (3–14 years) among patients favorable prognostic factors. However, other large series examining multimodality treatment y demonstrated modest improvement survival (median survival 14.5 months y 29.6% surviving 2 years). Reducing tumor cytoreductive surgery y extending survival. T surgeries developed: extrapleural pneumonectomy pleurectomy/decortication. T O A Oy indications performing these operations unique. T O A Oy choice operation depends patient's tumor. T important consideration because tumor volume identified prognostic factor mesothelioma. Pleurectomy/decortication spares underlying g performed patients early stage disease intention remove gross visible tumor (macroscopic complete resection), simply palliation. Extrapleural pneumonectomy extensive operation involves resection parietal visceral pleurae, underlying lung, ipsilateral diaphragm, ipsilateral pericardium. T operation indicated subset patients advanced tumors, tolerate pneumonectomy.